. "5 Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials." Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press, 2009.
Thulin, P., I. Rafter, K. Stockling, C. Tomkiewicz, E. Norjavaara, M. Aggerbeck, H. Hellmold, E. Ehrenborg, U. Andresson, I. Cotgreave, and B. Glinghammar. 2008. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicology and Applied Pharmacology 231(1):1–9.
Uetrecht, J. 2007. Idiosyncratic drug reactions: Current understanding. Annual Review ofPharmacology and Toxicology 47:513–539.
Watkins, P. B. 1998. Hepatic dysfunction associated with troglitazone. New England Journalof Medicine 338:916–917.
Watkins, P. B., H. J. Zimmerman, M. J. Knapp, S. I. Gracon, and K. W. Lewis. 1994. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. Journal of theAmerican Medical Association 271(13):992–998.
Watkins, P. B., P. J. Seligman, J. S. Pears, M. I. Avigan, and J. R. Senior. 2008. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48(5):1680–1689.
Wilke, R. A., D. W. Lin, D. M. Roden, P. B. Watkins, D. Flockhart, I. Zineh, K. M. Giacomini, and R. M. Krauss. 2007. Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nature Reviews Drug Discovery 7:904–916.
Xu, J. J., P. V. Henstock, M. C. Dunn, A. R. Smith, J. R. Chabot, and D. de Graaf. 2008. Cellular imaging predictions of clinical drug-induced liver injury. Toxicological Sciences 105:97–105.
Zimmerman, H. J. 1968. The spectrum of hepatotoxicity (Kober lecture). Perspectives inBiology and Medicine 12(1)135–161.